Pharsight

Uptravi patents expiration

UPTRAVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(2 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan
Aug, 2029

(5 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Jun, 2030

(6 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
Dec, 2036

(12 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Dec, 2036

(12 years from now)

Uptravi is owned by Actelion.

Uptravi contains Selexipag.

Uptravi has a total of 6 drug patents out of which 0 drug patents have expired.

Uptravi was authorised for market use on 29 July, 2021.

Uptravi is available in powder;intravenous dosage forms.

Uptravi can be used as method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan, method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag, method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag, method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag, method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag.

The generics of Uptravi are possible to be released after 01 December, 2036.

Drugs and Companies using SELEXIPAG ingredient

Market Authorisation Date: 29 July, 2021

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage

UPTRAVI family patents

Family Patents